Pain Management Drugs Market expected to reach USD 116.412 billion by 2030

Pain Management Drugs Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the pain management drugs market will expand from USD 91.628 billion in 2025 to USD 116.412 billion in 2030 at a CAGR of 4.90% during the forecast period.

Rapid advancements in drug development to treat chronic, acute, and postoperative pain conditions have positively impacted the market growth.

The growing prevalence of arthritis, cancer, neuropathic disorders, migraines, and musculoskeletal injuries has accelerated the demand for effective pharmacological solutions for pain treatment. Additionally, the drug manufacturers are heavily investing in advanced drug delivery systems that are more effective in terms of duration of action and deliver drug into the targeted site. The transition towards non-opioid pain medication has further provided safer alternatives for acute pain management.

Request a free sample copy or view the report summary: Pain Management Drugs Market Report

Pain Management Drugs Market Report Highlights

• The anticonvulsant drugs are expected to show considerable growth during the forecast period as gabapentinoids such as gabapentin and pregabalin are used in neuropathic pain and seizures. These drugs in contrast to opioids provide a safe way to modulate pain without the risk of addiction owing to which they have become a primary choice for doctors to reduce opioid addiction for pain management.  

• The cancer pain will account for a significant market share fueled by the continuous rise in cancer incidence worldwide that has led to longer treatment durations, thereby demanding a tighter integration of pain treatment into the oncological care pathways Similarly, the growing shift towards much accessible and personalized approach for pain relief has positively impacted the market demand.

• The transdermal is projected to grow at a steady rate as it provides a sustained and controlled drug release for long-term management which makes it ideal for treating chronic pain conditions such as in arthritis, and musculoskeletal disorder. Additionally, benefits provided by transdermal patches like maintaining plasma concentration levels steady, low gastrointestinal side effects, and improvement in the patient’s compliance with the therapy is further driving their preference oral and injectable forms of administration.

• The online pharmacies is anticipated to show quickest growth fueled by the rapidly growing digital healthcare followed by increased internet penetration which has increased consumer preference for online platforms for medicine purchase. Likewise, the price transparency and availability of a wide range of products is driving e-commerce adoption in pharmaceuticals. Also, the increasing number of chronic pain patients who need medication refills that are recurring makes online channels attractive in terms of convenience and cost savings.   

• North America is projected to account for a major market share due to the ongoing developments in advanced drug delivery in regional economies namely the United States. Additionally, well-established presence of major market players namely Sanofi, Pfizer, GlaxoSmithKline Plc and Merck which are showing constant participation in new drug development and clinical trials.

Pain Management Drugs Market Growth Drivers and Restraints

Growth Drivers:

• Rising Prevalence of Chronic Pain Conditions: A major factor driving the market growth is the growing global prevalence of chronic pain condition caused by disorders such as arthritis, cancer, and musculoskeletal degeneration. Major economies such as the United States is witnessing a high frequency of new cases, for instance according to the American Cancer Society, in 2025, the estimated number of new cancer cases reached 2,041,910 while number of deaths reached 618,120.

• Growing Elderly Population Worldwide: The elderly is more prone to chronic diseases and require long-term pain management which has accelerated the demand for non-invasive and painless drug delivery. With constant rise in old age population the preference of user-friendly option for pain management is expected to gain traction. According to the United Nations, the number of people aged 60 years and above reached 1.2 billion and by 2050 the number will reach 2.1 billion.

 Restraints:

• Stringent Regulatory Frameworks and Safety Concerns: Pain management medicines, most notably opioids and a few NSAIDs must undergo strict regulative control because they are associated with the risks of addiction, overdose, gastrointestinal complications, and cardiovascular side effects. Governing authorities such as Food and Drug Administration (FDA) have drafted guidelines which needs to be followed in pain management drugs development, for instance, in September 2025, FDA issued “Development of Non-Opioid Analgesics for Chronic Pain” to emphasize efficient drug development and reduce prescription-related opioid misuse.

• High risk of Side-Effect: Many medicines such as NSAIDs if used over time can cause various other health risk like stomach ulcers and kidney damage. Similarly, drugs like corticosteroids can cause metabolic complications, while constant opioids usage leads to constipation and nausea. Such side effects may impact the frequency of usage of such pain management drugs which can negatively impact their market demand.

Pain Management Drugs Market Key Developments

• Collaboration: In July 2025, Pacira BioSciences, Inc formed a collaboration with Johnson & Johnson’s MedTech to expand the market for Pacira’s extended-release injectable product “ZILRETTA” in the United States.

• Product Launch: In January 2025, Food and Drug Administration (FDA) approved Vertex Pharmaceutical Incorporated’s 50-miligram oral tablet “Journavx” which is used for treating moderate to acute severe pain in adults.

Pain Management Drugs Market Segmentation

Knowledge Sourcing Intelligence has segmented the pain management drugs market based on drug type, indication, drug delivery, distribution channel, and region:   

Pain Management Drugs Market, By Drug Type

• Opioids

• Nonsteroidal anti-inflammatory drugs (NSAIDs)

• Corticosteroids

• Acetaminophen

• Antidepressants

• Anticonvulsant drugs

• Local Anaesthetics

• Others

Pain Management Drugs Market, By Indication

• Cancer Pain

• Rheumatoid Arthritis

• Chronic Back Pain

• Post-Operative Pain

• Migraine and Headache Disorders

• Others

Pain Management Drugs Market, By Drug Delivery

• Oral

• Injectable

• Topical

• Transdermal

• Inhalation

• Others

Pain Management Drugs Market, By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

• Specialty Pharmacies

Pain Management Drugs Market, By Region

• North America

  • USA

  • Canada

  • Mexico

• South America

  • Brazil

  • Argentina

  • Others

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Others

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • Others

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Taiwan

  • Indonesia

  • Thailand

  • Others

Pain Management Drugs Market Key Players

• Novartis AG

• Eli Lilly and Company

• Pfizer Inc.

• GlaxoSmithKline plc

• Merck & Co., Inc.

• Sanofi S.A.

• Abbott Laboratories

• Johnson & Johnson

• Mallinckrodt Pharmaceuticals plc

• Viatris Inc.

• Teva Pharmaceuticals Industries Ltd.